Glaukos (NYSE:GKOS) this week posted first-quarter results that beat the overall consensus on Wall Street.
The San Clemente, California-based company reported profits of $5.4 million, or 11¢ per share, on sales of $67.7 million for the three months ended March 31, for a sales loss of -0.42% compared with Q1 2021.
Adjusted to exclude one-time items, earnings per share were -38¢, 13¢ ahead of The Street, where analysts were looking for sales of $60.85 million.
“I’m pleased with our first-quarter performance and execution of our strategies despite a challenging global environment,” CEO Thomas Burns said in a news release. “We continue to successfully invest in and advance our robust pipeline of novel, dropless platform technologies designed to transform vision by disrupting the standard of care and improving outcomes for the benefit of patients worldwide suffering from chronic eye diseases.”
Glaukos expects net sales for 2022 to be in the range of $270 million to $275 million.
Shares in GKOS were down 2.18% to $43.93 apiece in mid-morning trading.